Our products utilize a proprietary, dual-carrier transdermal drug delivery system, we call:
Advanced Penetration Technology™ (APT™)
APT™ has solved the absorption problem that has hindered previous attempts with enabling topically applied medications to penetrate the epidermis into the dermis and surrounding tissues safely. The APT™ within our lead product, Tetracycline 3% ointment, operates by disrupting the cell wall of the organism and flooding the organism with medication, causing a biochemical and mechanical kill of the organism.
APT™ has the added benefit of optimizing the local tissue environment for a more rapid healing process. APT™ dramatically improves penetration of many topical medications, allowing for maximal effectiveness of our topically applied products. The APT™ will be a key aspect of all our product offerings brought into the consumer healthcare marketplace.
Validating APT™ efficacy with GLP Laboratory Tests
We are happy to share our testing results under a confidentiality agreement.
Learn more about our products that utilize APT™.
COVID-19 (Coronavirus) is a pandemic with no immediate vaccines, treatments or preventative products
The United States and international health providers, pharmaceutical companies and governments are actively
working to fund these vital initiatives. Social distancing, with its associated shutdown of commerce
and normal routine appears, to be the best solution so far in preventing the spread of the COVID virus.
Based on scientific research, Advanced Penetration Technology, LLC strongly believes the proprietary APT™
based non-prescription (OTC) topical formulation, used off-label, will play an important role in
mitigating, decreasing and preventing the spread and severity of COVID-19 illness.
Recently concluded Anti-Viral Studies demonstrated the significant efficacy of the APT™ T3X formulation in
neutralizing the Influenza A virus (H1N1) and Coronavirus (NL63). The laboratory conclusion
was “Under the conditions tested, treatment of influenza A/WSN/33 virus
and Coronavirus NL63, with APT™ T3X formulation abolishes infectivity”. Further viral
testing is ongoing.
Decreasing the Viral Load of Exposure is the key to slowing and mitigating
the spread of COVID-19 virus. The daily use of APT™ T3X formulation as a nasal swab application will help
in the mitigation of the COVID-19 Pandemic.
- Application recommendations for Healthcare Workers, Military personnel, First Responders, (at) High
risk individuals and the General Public: Swabbing the formulation within each nasal cavity every
12 hours could reduce the exposure levels of the COVID-19 virus into the body, hence reducing
infectivity of the individual and decreasing transmission to others.
- Application recommendations for Non-symptomatic COVID-19 patients: Swabbing the product within
the nasal cavity every 12 hours to mitigate infectivity, transmission and progression of the
- APT™ T3X formulation use along with recommended CDC guidelines for COVID-19 prevention, together,
create another barrier to infection and transmission to fight this Pandemic.